Welcome to our dedicated page for Charles River Laboratories International news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles River Laboratories International stock.
Founded in 1947, Charles River Laboratories International, Inc. (symbol: CRL) is a global leader in providing essential products and services to pharmaceutical and biotechnology companies, government agencies, and academic institutions. The company's mission is to accelerate research and drug development efforts, significantly contributing to the healthcare industry.
Charles River operates through three main segments:
- Research Models & Services: This segment is renowned for being the leading provider of laboratory animal models. Charles River breeds and supplies animals with specific genetic traits for preclinical studies worldwide, supporting the critical early stages of drug discovery.
- Discovery & Safety Assessment: This segment offers a comprehensive range of services necessary for the early development of new drugs. From discovery services to safety assessments, Charles River helps clients navigate the complex process of taking a drug from concept to early-stage development.
- Manufacturing Support: This includes microbial solutions for in vitro testing, biologics testing services, and avian vaccine services. These services are integral to ensuring the safe manufacture and quality control of new therapies.
The company's workforce is dedicated to providing clients with the expertise and services they need to improve and expedite the discovery and development of new therapies. Charles River's collaborative approach and commitment to excellence have established it as a trusted partner in the life sciences industry.
Charles River continues to innovate and expand its services, making significant strides in the fields of drug discovery, biotechnology, and pharmaceuticals. With a strong financial footing and strategic partnerships, the company is well-positioned to support the future of healthcare advancements globally.
Charles River Laboratories (NYSE: CRL) has announced a collaboration with Sanofi to develop Virtual Control Groups (VCGs) in nonclinical toxicology. This initiative aims to reduce the use of animals in research by replacing some control group animals with data-driven virtual counterparts created from historical datasets. Guided by Charles River’s Alternative Methods Advancement Project (AMAP), this collaboration leverages machine learning and extensive data to generate meaningful study results without the need for as many animal subjects. The project is a pioneering effort to apply VCGs, commonly used in clinical trials, to preclinical research, involving partnerships with regulatory and biopharmaceutical leaders. The initiative aims to advance sustainable science in toxicology studies.
Charles River Laboratories (NYSE: CRL) will present at two upcoming conferences. The company will speak at the William Blair 44th Annual Growth Stock Conference on June 4th at 10:00 a.m. CT (11:00 a.m. ET) and at the Jefferies Global Healthcare Conference on June 5th at 10:00 a.m. ET. Management will discuss the company's strategic priorities, business developments, and industry trends. Live webcasts and replays will be available on the Investor Relations section of Charles River's website.
Charles River Laboratories has launched new Modular and Fast Track viral vector technology transfer frameworks. These frameworks are designed for seamless tech transfer to its Maryland-based viral vector Center of Excellence within nine months. The Fast Track framework allows for straightforward transfers when no process changes are needed, while the Modular framework supports complex transfers requiring process modifications. Both frameworks aim to prevent costly delays and ensure program success. Charles River's CoE offers full-scale capabilities for adeno-associated virus, adenovirus, lentivirus, and retrovirus production and integrates their concept-to-cure portfolio from discovery to commercialization.
Charles River Laboratories reported first-quarter 2024 results with revenue of $1.01 billion, GAAP EPS of $1.30, and Non-GAAP EPS of $2.27. The company updated its 2024 guidance and reaffirmed revenue growth and non-GAAP earnings per share estimates. Despite revenue declines in the DSA segment, the RMS and Manufacturing segments showed growth. The company aims to capitalize on new business opportunities in the biopharmaceutical sector.
Charles River Laboratories International, Inc. (NYSE: CRL) has launched viral vector reference materials to aid gene and cell therapy researchers, providing AAV and LVV products with high quality. The company aims to streamline the research and development process, offering superior serotypes and vector genome concentrations. The launch includes six AAV reference material serotypes and five LVV reference material products, contributing to their extensive CDMO offerings. The official launch will take place at the ASGCT Annual Meeting in May 2024, showcasing case study data and various presentations. Charles River's CGT portfolio and viral vector CDMO solutions aim to support client programs and assist in scaling from pre-clinical to commercial stages.
FAQ
What is the current stock price of Charles River Laboratories International (CRL)?
What is the market cap of Charles River Laboratories International (CRL)?
What services does Charles River Laboratories provide?
When was Charles River Laboratories founded?
Who are Charles River Laboratories' primary clients?
What is Charles River Laboratories' mission?
What is included in the Research Models & Services segment?
What does the Discovery & Safety Assessment segment offer?
What are some of the services provided under Manufacturing Support?
How does Charles River contribute to the healthcare industry?
What makes Charles River Laboratories a trusted partner in the life sciences industry?
What is the ticker symbol for Charles River Laboratories International, Inc.?
